



## International Journal of Research in Pharmaceutical and Nano Sciences

Journal homepage: [www.ijrpns.com](http://www.ijrpns.com)



### A REVIEW ON LIPOSOMES

Saraswathi Marripati\*<sup>1</sup>, K. Umasankar<sup>1</sup>, P. Jayachandra Reddy<sup>1</sup>

<sup>1</sup>\*Department of Pharmaceutics, Krishna Teja Pharmacy College, Chadalawada Nagar, Tirupathi, Andhra Pradesh, India.

#### ABSTRACT

Liposome's, sphere-shaped vesicles consisting of one or more phospholipids bilayers. Today, they are a very useful reproduction, reagent, and tool in various scientific disciplines, including mathematics and theoretical physics, biophysics, chemistry, colloid science, biochemistry, and biology. A number of clinical studies have now demonstrated the superiority of liposomal drug formulations over conventional delivery systems. Liposomes characterize an advanced technology to deliver active molecules to the site of action, and at present, several formulations are in clinical use. Research on liposome technology has progressed from conventional vesicles to 'second-generation liposome's', in which long-circulating liposome's are obtained by modulating the lipid composition, size, and charge of the vesicle. Liposome with modified surfaces have also been developed using several molecules, such as glycolipids or sialic acid. Antineoplastic agents, doxorubicin, daunorubicin and cytarabine, are in advanced stages of clinical testing in humans. One or more of these should prove to be a medically useful and commercially viable product within the next few years. This paper summarizes exclusively scalable techniques and focuses on strengths, respectively, limitations in respect to industrial applicability and regulatory requirements concerning liposomal drug formulations based on FDA and EMEA documents.

#### KEYWORDS

Liposome, Glycolipids, Drug formulations and Drug delivery systems.

#### Author for Correspondence:

Saraswathi Marripati,  
Department of Pharmaceutics,  
Krishna Teja Pharmacy College,  
Chadalawada Nagar, Tirupathi,  
Andhra Pradesh, India.

**Email:** saraswathimarripati@gmail.com

#### INTRODUCTION

Liposome's are colloidal, vesicular structures composed of one or more lipid bilayers surrounding an equal numbers of aqueous compartments<sup>1</sup>. The sphere like shell encapsulated a liquid interior which contain substances such as peptides and protein, hormones, enzymes, antibiotic, anti-fungal and anticancer agents. A free drug injected in blood stream typically achieves therapeutic level for short duration due to metabolism and excretion. Drug

encapsulated by liposome achieve therapeutic level for long duration as drug must first be release from liposome before metabolism & excretion. They are small artificial vesicles of spherical shape that can be created from cholesterol and natural non-toxic phospholipids. Due to their size and hydrophobic and hydrophilic character (besides biocompatibility), liposome's are promising systems for drug delivery. Liposome properties differ considerably with lipid composition, surface charge, size, and the method of preparation. Furthermore, the choice of bilayer components determines the rigidity or fluidity and the charge of the bilayer. For instance, unsaturated phosphatidylcholine species from natural sources (egg or soybean phosphatidylcholine) give much more permeable and less stable bilayers, whereas the saturated phospholipids with long acyl chains. (For example, dipalmitoyl-phosphatidyl choline) form a rigid, rather impermeable bilayer structure<sup>2</sup>. It has been displayed that phospholipids impulsively form closed structures when they are hydrated in aqueous solutions. Such vesicles which have one or more phospholipids bilayer membranes can transport aqueous or lipid drugs, depending on the nature of those drugs. Because lipids are amphipathic (both hydrophobic and hydrophilic) in aqueous media, their thermodynamic phase properties and self-assembling characteristics influence entropically focused confiscation of their hydro-phobic sections into spherical bilayers. Those layers are referred to as lamellae. Generally, liposome's are Spherical vesicles with particle sizes ranging from 30 nm to several micrometers. They consist of one or more lipid bilayers surrounding aqueous units, where the polar head groups are oriented in the pathway of the interior and exterior aqueous phases. On the other hand, self-aggregation of polar lipids is not limited to conventional bilayer structures which rely on molecular shape, temperature, and environmental and preparation conditions but may self-assemble into various types of colloidal particles.

A liposome is an artificially-prepared spherical vesicle composed of a lipid bilayer. The liposome

can be used as a vehicle for administration of nutrients and pharmaceutical drugs<sup>3</sup>. Liposome's can be prepared by disrupting biological membrane (such as sonication). Liposome's are often composed of phosphatidylcholine-enriched phospholipids and may also contain mixed lipid chains with surfactant properties such as egg or phosphatidyl ethanolamine.

#### **Advantages and disadvantages of liposome**

Suitable for delivery of hydrophobic, amphipathic and hydrophilic drugs. Protect the encapsulated drug from the external environment. Reduced toxicity and increased stability<sup>4</sup>. As therapeutic activity of chemotherapeutic agents can be improved through liposome encapsulation. This reduces deleterious effects that are observed at conc. similar to or lower than those required for maximum therapeutic activity.

Reduce exposure of sensitive tissues to toxic drugs. Non-ionic can carry both water and lipid soluble drugs<sup>5</sup>. Biodegradable drugs can be stabilized from oxidation. Improve protein stabilization. Controlled hydration. Provide sustained release. Targeted drug delivery or site specific drug delivery. Stabilization of entrapped drug from hostile environment. Alter pharmacokinetics and pharmacodynamics of drugs. Can be administered through various routes. Can incorporate micro and macromolecules act as reservoir of drugs. Therapeutic index of drugs is increased. Site avoidance therapy can modulate the distribution of drug. Direct interaction of the drug with cell Biodegradable and flexible<sup>6</sup>.

#### **Disadvantages**

Less stability, Low solubility, Short half-life and Phospholipids undergoes oxidation, hydrolysis. Leakage and fusion. High production cost. Quick uptake by cells of R.E.S. Allergic reactions may occur to liposomal constituents<sup>7</sup>.

Phospholipids impulsively form closed structures when they are hydrated in aqueous solutions. Such vesicles which have one or more phospholipid bilayer membranes can transport aqueous or lipid drugs, depending on the nature of those drugs. Because lipids are amphipathic (both hydrophobic and hydrophilic) in aqueous media, their

thermodynamic phase properties and self-assembling characteristics influence entropically focused confiscation of their hydrophobic sections into spherical bilayers. Those layers are referred to as lamellae. Self-aggregation of polar lipids is not limited to conventional bilayer structures which rely on molecular shape, temperature, and environmental and preparation conditions but may self-assemble into various types of colloidal particles.

Liposomes are extensively used as carriers for numerous molecules in cosmetic and pharmaceutical industries. Additionally, food and farming industries have extensively studied the use of liposome encapsulation to grow delivery systems that can entrap unstable compounds (for example, antimicrobials, antioxidants, flavors and bioactive elements) and shield their functionality. Liposomes can trap both hydrophobic and hydrophilic compounds, avoid decomposition of the entrapped combinations, and release the entrapped at designated targets<sup>8</sup>.

Because of their biocompatibility, biodegradability, low toxicity, and aptitude to trap both hydrophilic and lipophilic drugs and simplify site-specific drug delivery to tumor tissues. Liposomes have increased rate both as an investigational system and commercially as a drug-delivery system. Many studies have been conducted on liposomes with the goal of decreasing drug toxicity and/or targeting specific cells.

One of the main aims of any cure employing drug is to increase the therapeutic index of the drug while minimizing its side effects. The clinical usefulness of most conservative chemotherapeutics is restricted either by the incapability to deliver therapeutic drug concentrations to the target soft tissue or by Spartan and harmful toxic side effects on normal organs and tissues. Different approaches have been made to overcome these difficulties by providing the 'selective' delivery to the target area; the ideal solution would be to target the drug alone to those cells, tissues, organs that are affected by the disease. Selected carriers, for instance colloidal

particulates and molecular conjugates, can be appropriate for this determination.

### **Aim and Objectives**

The present review will briefly explain the characteristics of liposomes and explore the related problems and solutions proposed, with a focus on liposome preparation, characterizations, affecting factors, advantages, and disadvantages. In particular, we return to the literature relating to high-stability, long-circulating liposomes (stealth liposomes), and their field of application.

### **Classification of liposomes**

The liposome size can vary from very small (0.025  $\mu\text{m}$ ) to large (2.5  $\mu\text{m}$ ) vesicles. Moreover, liposomes may have one or bilayer membranes. The vesicle size is an acute parameter in determining the circulation half-life of liposomes, and both size and number of bilayers affect the amount of drug encapsulation in the liposomes<sup>9</sup>.

On the basis of their size and number of bilayers, liposomes can also be classified into one of two categories: (1) multilamellar vesicles (MLV) and (2) unilamellar vesicles. Unilamellar vesicles can also be classified into two categories: (1) large unilamellar vesicles (LUV) and (2) small unilamellar vesicles (SUV). In unilamellar liposome's, the vesicle has a single phospholipids bilayer sphere enclosing the aqueous solution. In multilamellar liposome's, vesicles have an onion structure<sup>10</sup>. Classically, several unilamellar vesicles will form on the inside of the other with smaller size, making a multilamellar structure of concentric phospholipids spheres separated by layers of water.

## **METHODS OF LIPOSOME PREPARATION**

### **Method of liposome preparation and drug loading**

The following methods are used for the preparation of liposome:

- Passive loading techniques
- Active loading technique.

Passive loading techniques include three different methods:

- Mechanical dispersion method.
- Solvent dispersion method.

- Detergent removal method (removal of non-encapsulated material).

### **Mechanical dispersion method**

The following are types of mechanical dispersion methods:

- Sonication.
- French pressure cell: extrusion.
- Freeze-thawed liposome's.
- Lipid film hydration by hand shaking, non-hand shaking or freeze drying.
- Micro-emulsification.
- Membrane extrusion.
- Dried reconstituted vesicles.

### **Sonication**

Sonication is perhaps the most extensively used method for the preparation of SUV. Here, MLVs are sonicated either with a bath type sonicator or a probe sonicator under a passive atmosphere<sup>11</sup>. The main disadvantages of this method are very low internal volume/encapsulation efficacy, possible degradation of phospholipids and compounds to be encapsulated, elimination of large molecules, metal pollution from probe tip, and presence of MLV along with SUV.

### **There are two sonication techniques**

1. Probe sonication. The tip of a sonicator is directly engrossed into the liposome dispersion. The energy input into lipid dispersion is very high in this method. The coupling of energy at the tip results in local hotness; therefore, the vessel must be engrossed into a water/ice bath. Throughout the sonication up to 1 h, more than 5% of the lipids can be de-esterified. Also, with the probe sonicator, titanium will slough off and pollute the solution.
2. Bath sonication. The liposome dispersion in a cylinder is placed into a bath sonicator. Controlling the temperature of the lipid dispersion is usually easier in this method, in contrast to sonication by dispersal directly using the tip. The material being sonicated can be protected in a sterile vessel, dissimilar the probe units, or under an inert atmosphere.

### **French pressure cell: extrusion**

French pressure cell involves the extrusion of MLV through a small orifice. An important feature of the French press vesicle method is that the proteins do not seem to be significantly pretentious during the procedure as they are in sonication. An interesting comment is that French press vesicle appears to recall entrapped solutes significantly longer than SUVs do, produced by sonication or detergent removal.

The method involves gentle handling of unstable materials. The method has several advantages over sonication method. The resulting liposomes are rather larger than sonicated SUVs. The drawbacks of the method are that the high temperature is difficult to attain, and the working volumes are comparatively small (about 50 mL as the maximum).

### **Freeze-thawed liposomes**

SUVs are rapidly frozen and thawed slowly. The short-lived sonication disperses aggregated materials to LUV. The creation of unilamellar vesicles is as a result of the fusion of SUV throughout the processes of freezing and thawing. This type of synthesis is strongly inhibited by increasing the phospholipid concentration and by increasing the ionic strength of the medium. The encapsulation efficacies from 20% to 30% were obtained.

### **Solvent dispersion method**

#### **Ether injection (solvent vaporization)**

A solution of lipids dissolved in diethyl ether or ether-methanol mixture is gradually injected to an aqueous solution of the material to be encapsulated at 55°C to 65°C or under reduced pressure<sup>12</sup>. The consequent removal of ether under vacuum leads to the creation of liposomes. The main disadvantages of the technique are that the population is heterogeneous (70 to 200 nm) and the exposure of compounds to be encapsulated to organic solvents at high temperature.

#### **Ethanol injection**

A lipid solution of ethanol is rapidly injected to a huge excess of buffer. The MLVs are at once formed. The disadvantages of the method are that

the population is heterogeneous (30 to 110 nm), liposome's are very dilute, the removal all ethanol is difficult because it forms into azeotrope with water, and the probability of the various biologically active macromolecules to inactivate in the presence of even low amounts of ethanol is high.

#### **Reverse phase evaporation method**

This method provided a progress in liposome technology, since it allowed for the first time the preparation of liposomes with a high aqueous space-to-lipid ratio and a capability to entrap a large percentage of the aqueous material presented. Reverse-phase evaporation is based on the creation of inverted micelles. These inverted micelles are shaped upon sonication of a mixture of a buffered aqueous phase, which contains the water-soluble molecules to be encapsulated into the liposomes and an organic phase in which the amphiphilic molecules are solubilized. The slow elimination of the organic solvent leads to the conversion of these inverted micelles into viscous state and gel form. At a critical point in this process, the gel state collapses, and some of the inverted micelles were disturbed. The excess of phospholipids in the environment donates to the formation of a complete bilayer around the residual micelles, which results in the creation of liposomes. Liposomes made by reverse phase evaporation method can be made from numerous lipid formulations and have aqueous volume-to-lipid ratios that are four times higher than hand-shaken liposomes or multilamellar liposomes.

Briefly, first, the water-in-oil emulsion is shaped by sonication of a two-phase system, containing phospholipids in organic solvent such as isopropyl ether or diethyl ether or a mixture of isopropyl ether and chloroform with aqueous buffer. The organic solvents are detached under reduced pressure, resulting in the creation of a viscous gel. The liposomes are shaped when residual solvent is detached during continued rotary evaporation under reduced pressure. With this method, high encapsulation efficiency up to 65% can be obtained

in a medium of low ionic strength. Example 0.01 M NaCl.

The method has been used to encapsulate small, large, and macromolecules. The main drawback of the technique is the contact of the materials to be encapsulated to organic solvents and to brief periods of sonication. These conditions may possibly result in the breakage of DNA strands or the denaturation of some proteins. Modified reverse phase evaporation method was presented by Handa et al., and the main benefit of the method is that the liposomes had high encapsulation efficiency (about 80%).

#### **Detergent removal method (removal of non-encapsulated material)**

##### **Dialysis**

The detergents at their critical micelle concentrations (CMC) have been used to solubilize lipids. As the detergent is detached, the micelles become increasingly better-off in phospholipid and lastly combine to form LUVs. The detergents were removed by dialysis. A commercial device called LipoPrep (Diachema AG, Switzerland), which is a version of dialysis system, is obtainable for the elimination of detergents. The dialysis can be performed in dialysis bags engrossed in large detergent free buffers (equilibrium dialysis).

##### **Detergent (cholate, alkyl glycoside, Triton X-100) removal of mixed micelles (absorption)**

Detergent absorption is attained by shaking mixed micelle solution with beaded organic polystyrene adsorbers such as XAD-2 beads (SERVA Electrophoresis GmbH, Heidelberg, Germany) and Bio-beads SM2 (Bio-Rad Laboratories, Inc., Hercules, USA). The great benefit of using detergent adsorbers is that they can eliminate detergents with a very low CMC, which are not entirely depleted.

##### **Gel-permeation chromatography**

In this method, the detergent is depleted by size special chromatography. The liposomes do not penetrate into the pores of the beads packed in a column. They percolate through the inter-bead spaces. At slow flow rates, the separation of liposomes from detergent monomers is very good.

The swollen polysaccharide beads adsorb substantial amounts of amphiphilic lipids; therefore, pre-treatment is necessary. The pre-treatment is done by pre-saturation of the gel filtration column by lipids using empty liposome suspensions<sup>13</sup>.

#### **Dilution**

Upon dilution of aqueous mixed micellar solution of detergent and phospholipids with buffer, the micellar size and the polydispersity increase fundamentally, and as the system is diluted beyond the mixed micellar phase boundary, a spontaneous transition from polydispersed micelles to vesicles occurs.

#### **Drug loading in liposomes**

Drug loading can be attained either passively (i.e., the drug is encapsulated during liposome formation) or actively (i.e., after liposome formation). Hydrophobic drugs, for example amphotericin B taxol or anamycin, can be directly combined into liposomes during vesicle formation, and the amount of uptake and retention is governed by drug-lipid interactions. Trapping effectiveness of 100% is often achievable, but this is dependent on the solubility of the drug in the liposome membrane. Passive encapsulation of water-soluble drugs depends on the ability of liposomes to trap aqueous buffer containing a dissolved drug during vesicle formation. Trapping effectiveness (generally <30%) is limited by the trapped volume delimited in the liposomes and drug solubility. On the other hand, water-soluble drugs that have protonizable amine functions can be actively entrapped by employing pH gradients, which can result in trapping effectiveness approaching 100%.

#### **Freeze-protectant for liposomes (lyophilization)**

Natural excerpts are usually degraded because of oxidation and other chemical reactions before they are delivered to the target site. Freeze-drying has been a standard practice employed to the production of many pharmaceutical products. The overwhelming majority of these products are lyophilized from simple aqueous solutions. Water is the only solvent that must be detached from the solution using the freeze-drying process.

Freeze-drying (lyophilization) involves the removal of water from products in the frozen state at tremendously low pressures. The process is normally used to dry products that are thermo-labile and would be demolished by heat-drying. The technique has too much potential as a method to solve long-term stability difficulties with admiration to liposomal stability. Studies showed that leakage of entrapped materials may take place during the process of freeze-drying and on reconstitution. Newly, it was shown that liposomes when freeze-dried in the presence of adequate amounts of trehalose (a carbohydrate commonly found at high concentrations in organism) retained as much as 100% of their original substances. It shows that trehalose is an excellent cryoprotectant (freeze-protectant) for liposome.

#### **Purification of liposome**

Liposomes are generally purified by gel filtration chromatography<sup>14</sup>, Dialysis and centrifugation. In chromatographic separation, Sephadex-50 is most widely used. In dialysis method hollow fibre dialysis cartridge maybe used. In centrifugation method, SUVs in normal saline may be separated by centrifuging at 200000 g, for 10-20hours. MLVs are separated by centrifuging at 100000g for less than one hour.

#### **Mechanism of transportation through liposome**

The limitations and benefits of liposome drug carriers lie critically on the interaction of liposomes with cells and their destiny *in vivo* after administration. *In vivo* and *in vitro* studies of the contacts with cells have shown that the main interaction of liposomes with cells is either simple adsorption (by specific interactions with cell-surface components, electrostatic forces, or by non-specific weak hydrophobic) or following endocytosis (by phagocyte cells of the reticulo-endothelial system, for example macrophages and neutrophils). Fusion with the plasma cell membrane by insertion of the lipid bilayer of the liposome into the plasma membrane, with simultaneous release of liposomal content into the cytoplasm, is much rare. The fourth possible interaction is the exchange of bilayer components, for instance cholesterol, lipids,

and membrane-bound molecules with components of cell membranes.

## EVALUATION OF LIPOSOMES

Liposomal formulation and processing for specified purpose are characterized to ensure their predictable *in vitro* and *in vivo* performance. The characterization parameters for purpose of evaluation could be classified into three broad Categories, which include physical, chemical and biological parameters. Physical characterization evaluates various parameters including size, shape, surface features, lamellarity phase-behaviour and drug release profile. Chemical characterization includes those studies which establish the purity and potency of various lipophilic constituents. Biological characterization parameters are helpful in establishing the safety and suitability of formulation for therapeutic application. Some of parameters are:

### Vesicle shape and lamellarity

Vesicle shape can be assessed using electron Microscopic Techniques. Lamellarity of vesicles i.e. number of bilayers presents in liposome's is determined using Freeze Fracture Electron Microscopy and P31 Nuclear Magnetic Resonance Analysis.

### Vesicle size and size distribution

Various techniques are described in literature for determination of size and size distribution. These include Light Microscopy, Fluorescent Microscopy, Electron Microscopy (Transmission Electron Microscopy), Laser light scattering Photon correlation Spectroscopy, Field Flow fractionation, Gel Permeation and Gel Exclusion. The most precise method of determine size of liposome is Electron Microscopy. It is very time consuming and require equipments that may not always be immediately to hand. In contrast, laser light scattering method is very simple and rapid to perform but having disadvantage of measuring an average property of bulk of liposomes. Another more recently developed microscopic technique known as atomic force microscopy has been utilized to study liposome morphology, size, and

stability<sup>15</sup>. Most of methods used in size, shape and distribution analysis can be grouped into various categories namely microscopic, diffraction, scattering, and hydrodynamic techniques.

### Microscopic Techniques

#### Optical Microscopy

The microscopic method includes use of Bright-Field, phase-Contrast Microscope and Fluorescent Microscope and is useful in evaluating vesicle size of large vesicles<sup>16</sup>.

#### Cryo-Transmission Electron Microscopy Techniques (cryo-TEM)

This technique has been used to elucidate the surface morphology and size of vesicles.

#### Diffraction and Scattering Techniques

**Laser Light Scattering Photon correlation spectroscopy (PCS)** is analysis of time dependence of intensity fluctuation in scattered laser light due to Brownian motion of particles in solution/suspension. Since small particles diffuse more rapidly than large particles, the rate of fluctuation of scattered light intensity varies accordingly. Thus, the translational diffusion coefficient (D) can be measured, which in turn can be used to determine the mean hydrodynamic radius (Rh) of particles using the Stoke-Einstein equation. Using this technique one can measure particles in range of about 3nm.

#### Hydrodynamic Techniques

This technique includes gel Permeation and Ultracentrifuge. Exclusion chromatography on large pure gels was introduced to separate SUVs from radial MLVs. However, large vesicles of 1-3µmdiameter usually fail to enter the gel and are retained on top of column. A thin layer chromatography system using agarose beads has been introduced as a convenient, fast technique for obtaining a rough estimation of size distribution of liposome preparation. However, it was not reported if this procedure was sensitive to a physical blockage of pores of the agarose gel as is the more conventional column chromatography.

### **Encapsulation Efficiency**

Determine amount and rate of entrapment of water-soluble agents in aqueous compartment of liposome.

### **Applications of liposomes in medicine and pharmacology**

Applications of liposomes in medicine and pharmacology can be divided into diagnostic and therapeutic applications of liposomes containing various markers or drugs, and their use as a tool, a model, or reagent in the basic studies of cell interactions, recognition processes, and mode of action of certain substances.

Unfortunately, many drugs have a very narrow therapeutic window, meaning that the therapeutic concentration is not much lower than the toxic one. In several cases, the toxicity can be reduced or the efficacy can be enhanced by the use of a suitable drug carrier which alters the temporal and spatial delivery of the drug, i.e., its biodistribution and pharmacokinetics. It is clear from many pre-clinical and clinical studies that drugs, for instance antitumor drugs, parceled in liposome demonstration reduced toxicities, while retentive enhanced efficacy.

Advances in liposome design are leading to new applications for the delivery of new biotechnology products, for example antisense oligo-nucleotides, cloned genes, and recombinant proteins. A vast literature define the viability of formulating wide range of conservative drugs in liposomes, frequently resultant in improved therapeutic activity and/or reduced toxicity compared with the free drug. Changed pharmacokinetics for liposomal drugs can lead to improved drug bioavailability to particular target cells that live in the circulation, or more prominently, to extravascular disease sites, for example, tumors. Recent improvements include liposomal formulations of all-*trans*-retinoic acid and daunorubicin, as first-line treatment of AIDS-related advanced Kaposi's sarcoma. Examples are vincristine, doxorubicin, and amphotericin B.

The benefits of drug load in liposomes, which can be applied as (colloidal) solution, aerosol, or in

(semi) solid forms, such as creams and gels, can be summarized into seven categories

### **Benefits of drug load in liposomes**

#### **Liposomes in parasitic diseases and infections**

From the time when conventional liposomes are digested by phagocytic cells in the body after intravenous management, they are ideal vehicles for the targeting drug molecules into these macrophages. The best known instances of this 'Trojan horse-like' mechanism are several parasitic diseases which normally exist in the cell of MPS<sup>17</sup>. They comprise leishmaniasis and several fungal infections.

Leishmaniasis is a parasitic infection of macrophages which affects over 100 million people in tropical regions and is often deadly. The effectual dose of drugs, mostly different antimonials, is not much lower than the toxic one. Liposomes accumulate in the very same cell population which is infected, and so an ideal drug delivery vehicle was proposed. Certainly, the therapeutic index was increased in rodents as much as several hundred times upon administration of the drug in various liposomes. These formulations use mostly ionosphere amphotericin B and are transplanted from very successful and prolific area of liposome formulations in antifungal therapy.

The best results reported so far in human therapy are probably liposomes as carriers for amphotericin B in antifungal therapies. This is the drug of choice in dispersed fungal infections which often in parallel work together with chemotherapy, immune system, or AIDS, and is frequently fatal. Unfortunately, the drug itself is very toxic and its dosage is limited due to its ionosphere and neurotoxicity. These toxicities are normally related with the size of the drug molecule or its complex. Obviously, liposome encapsulation inhibits the accumulation of drug in these organs and radically reduces toxicity. Furthermore, often, the fungus exists in the cells of the mononuclear phagocytic system; therefore, the encapsulation results in reduced toxicity and passive targeting. These benefits, however, can be associated with any colloidal drug carrier. Certainly, similar



improvements in therapy were observed with stable mixed micellar formulations and micro-emulsions. Additionally, it seems that many of the early liposomal preparations were in actual fact liquid crystalline colloidal particles rather than self-closed MLV. Since the lives of the first terminally ill patients (who did not rely to all the conventional therapies) were saved, many patients were very effectively treated with diverse of amphotericin B formulations.

Comparable methods can be achieved in antiviral and antibacterial therapies. Most of the antibiotics, however, are orally available; liposome encapsulation can be considered only in the case of very potent and toxic ones which are administered parenterally. The preparation of antibiotic-loaded liposomes at sensibly high drug-to-lipid ratios may not be easy because of the interactions of these molecules with bilayers and high densities of their aqueous solutions which often force liposomes to float as a creamy layer on the top of the tube<sup>19</sup>. Several other ways, for instance, topical or pulmonary (by inhalation) administration are being considered also. Liposome-encapsulated antivirals (for example ribavirin, azidothymidine, or acyclovir) have also shown to reduce toxicity; currently, more detailed experiments are being performed in relation to their efficacy.

#### **Liposomes in anticancer therapy**

Numerous different liposome formulations of numerous anticancer agents were shown to be less toxic than the free drug. Anthracyclines are drugs which stop the growth of dividing cells by intercalating into the DNA and, thus, kill mainly rapidly dividing cell<sup>18</sup>. These cells are not only in tumors but are also in hair, gastrointestinal mucosa, and blood cells; therefore, this class of drug is very toxic. The most used and studied is Adriamycin. In addition to the above-mentioned acute toxicities, its dosage is limited by its increasing cardio toxicity. Numerous diverse formulations were tried. In most cases, the toxicity was reduced to about 50%. These include both acute and chronic toxicities because liposome encapsulation reduces the delivery of the drug molecules towards those tissues. For the same

reason, the efficiency was in many cases compromised due to the reduced bioavailability of the drug, especially if the tumor was not phagocytic or located in the organs of mononuclear phagocytic system. In some cases, such as systemic lymphoma, the effect of liposome encapsulation showed enhanced efficacy due to the continued release effect, i.e., longer presence of therapeutic concentrations in the circulation, while in several other cases, the sequestration of the drug into tissues of mononuclear phagocytic system actually reduced its efficacy.

#### **Other Applications**

- Gene therapy
- Liposomes as carriers for vaccines
- Liposomes as carrier of drug in oral treatment
- Liposomes for topical applications
- Liposomes for pulmonary delivery
- Against Leishmaniasis
- Lysosomal storage disease
- Cell biological application
- Metal storage disease
- Ophthalmic delivery of drugs.

#### **Therapeutic applications of liposomes**

##### **Liposome as drug/protein delivery vehicle**

Controlled and sustained drug release insitu. Enhanced drug solubilization, Altered pharmacokinetic and biodistribution. Enzyme replacement therapy and lysosomal disorders.

##### **Liposome in antimicrobial, antifungal and antiviral therapy**

Liposomal drugs

Liposomal biological response modifier

##### **Liposomes in tumour therapy**

Carrier of small cytotoxic molecule. Vehicle for macromolecule as cytokines or genes.

##### **Liposome in gene therapy**

Gene and antisense therapy, Genetic (DNA) vaccination

##### **Liposome in immunology**

Immunoadjuvant. Immunomodulator and Immunodiagnosis, Liposome as artificial blood surrogates, Liposomes as radiopharmaceutical and radio-diagnostic carrier. Liposomes in cosmetics

and dermatology. Liposomes in enzyme immobilization and bioreactor technology.

### Limitation in liposome technology

- Stability
- Sterilization
- Encapsulation efficiency
- Active targeting
- Gene therapy
- Lysosomal degradation

### CONCLUSION

Liposomes have been used in a broad range of pharmaceutical applications. Liposomes are showing particular promise as intracellular delivery systems for anti-sense molecules, ribosomes, proteins/peptides, and DNA. Liposomes with enhanced drug delivery to disease locations, by ability of long circulation residence times, are now achieving clinical acceptance. Also, liposomes promote targeting of particular diseased cells within the disease site. Finally, liposomal drugs exhibit reduced toxicities and retain enhanced efficacy compared with free complements. However, based on the pharmaceutical applications and available products, we can say that liposome's have definitely established their position in modern delivery systems. The use of liposomes in the delivery of drugs and genes are promising and is sure to undergo further developments in future.

### ACKNOWLEDGEMENT

I would like to thanks Krishna Teja Pharmacy College Chadalawada Nagar, Tirupathi, Andhra Pradesh, India for continuous support and encouragement throughout this work.

### CONFLICT OF INTEREST

We declare that we have no conflict of interest.

### REFERENCES

1. Torchilin V. Multifunctional nanocarriers, *Advanced Drug Delivery Reviews*, 58(14), 2006, 1532-55.
2. Kimball's Biology Pages, Cell Membranes.
3. Explanation on twst.com commercial page, cf. also Int.Patent PCT/US2008/074543 on, 4, section 0014.
4. Stryer S. *Biochemistry*, 18(4), 1981, 213-260.
5. Bangham A D, Horne R W. Negative Staining of Phospholipids and Their Structural Modification by Surface-Active Agents As Observed in the Electron Microscope, *Journal of Molecular Biology*, 8(5), 1964, 660-668.
6. Horne R W, Bangham A D, Whittaker V P. Negatively Stained Lipoprotein Membranes, *Nature*, 200(4913), 1963, 1340-1340.
7. Bangham A D, Horne R W, Glauert A M, Dingle J T, Lucy J A. Action of saponin on biological cell membranes, *Nature*, 196(4858), 1962, 952-955.
8. Yash Roy R C. Lamellar dispersion and phase separation of chloroplast membrane lipids by negative staining electron microscopy, *Journal of Biosciences*, 15(2), 1990, 93-98.
9. Bertrand, Nicolas Bouvet, Ce Line Moreau, Pierre, Leroux, Jean-Christophe. Transmembrane pH-Gradient Liposomes to Treat Cardiovascular Drug Intoxication, *ACS Nano*, 4(12), 1990, 7552-8.
10. Barani H, Montazer M. A review on applications of liposomes in textile processing, *Journal of liposome research*, 18(3), 2008, 249-262.
11. Meure LA, Knott R, Foster N R, Dehghani F. The depressurization of an expanded solution into aqueous media for the bulk production of liposomes, *Langmuir the ACS journal of surfaces and colloids* 25(1), 2009, 326-37.
12. Yoko Shojia, Hideki Nakashima. Nutraceuticals and Delivery Systems, *Journal of Drug Targeting*, 12(6), 2004, 385-391.
13. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans, II. Review of 93 intervention studies, *The*

- American journal of clinical nutrition*, 81(1), 2006, 243-255.
14. Bender, David A. *Nutritional Biochemistry of Vitamins*, Cambridge, U.K, 2(2), 2012, 449-455.
  15. Szoka J R, Papahadjopoulos, D. Comparative properties and methods of preparation of lipid vesicles (liposomes). *Annual review of biophysics and bioengineering*, 9(9), 1980, 467-508.
  16. Chaize B, Colletier J P, Winterhalter, M, Fournier D. Encapsulation of enzymes in liposomes: High encapsulation efficiency and
  17. Control of substrate permeability, *Artificial cells, blood substitutes, and immobilization biotechnology*, 32(1), 2014, 67-75.
  18. Gomezzens A, Fernandezromero J. Analytical methods for the control of liposomal delivery systems, *Tr AC Trends in Analytical Chemistry*, 25(2), 2006, 167.
  19. Mozafari M R, Johnson C, Hatziantoniou S, Demetzos C. Nanoliposomes and their applications in food nanotechnology, *Journal of liposome research*, 18(4), 2008, 309-27.
  20. Mozafari M R and Mortazavi S M. *Nanoliposomes: From Fundamentals to Recent Developments*, Oxford, UK, Trafford Publishing Ltd, 86(13), 2006, 2038-2045.

**Please cite this article in press as:** Saraswathi MARRIPATI. *et al.* A review on liposomes, *International Journal of Research in Pharmaceutical and Nano Sciences*, 3(3), 2014, 159-169.